......................................................................................
Assuming the UBS analyst who covered Quintis has lost their job.
UBS
11/05/2017
1
Buy
$3.20
984.75%
Quintis' one and only pharma customer has terminated its contract. Galderma acquired a competing acne brand back in March, leading the broker to question corporate governance given a long delay to disclosure. The termination also likely kills off any idea of a pharma spin-off.
That leaves wood sales to China, where the risk is prices are not as healthy and the recent negative publicity the company has ensured has an impact. The broker nevertheless retains Buy and $3.20 target.
- Forums
- ASX - By Stock
- QIN
- Ann: Annual Report to shareholders
Ann: Annual Report to shareholders, page-10
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)